Close Ad

The Spoon

Daily news and analysis about the food tech revolution

cultured protein

A Spanish Dairy Company Has Launched a Startup Incubator to Help Cultured Milk Companies

Pascual Innoventures, the open innovation arm of Spanish dairy company Calidad Pascual, has launched what it says is the world’s first incubator program for cellular agriculture in the dairy industry. Dubbed Mylkubator, the program will select and work with startups hoping to change the dairy industry through the development of alternative proteins. 

The program, which is supported by investment network Eatable Adventures and technology partner CNTA, will choose up to 10 startups to join the six-month hybrid program. Either in-person or virtually (or both), companies will work with mentors and get access to Pascual’s R&D facilities to develop and test their products. 

On a high level, cultured milk is created by growing mammary gland cells in an external environment (like a bioreactor) that mimics the one found inside mammals (like a cow). Micronutrients get converted into milk, which can then be harvested and purified. The process requires expertise in a number of different areas, from cell-growth media to machine learning modules that can optimize the production process. Different types of milk, including cow’s milk and human breastmilk, can be made from this process.

To that end, novel growth media, cell-growth techniques, and improvement of cell lines are among the topics the program says it is looking to find companies. And in addition to cellular ag, startups working with fermentation-based solutions or developing applied technologies like machine learning and biorecators are also welcome to apply. 

In the realm of alternative protein, the number of well-known companies currently developing milk analogues via cellular agriculture is still pretty small, particularly in comparison to the glut of cell-based meat makers. Turtle Tree Labs and Biomilq are the most well-known companies at this point.

On the other hand, companies like Perfect Day and ReMilk make milk analogues via fermentation, a process now seen as the third-pillar of alternative protein.  

Startups working with both methods are invited to apply for Mylkubator’s program. Those chosen will get a chance to prototype, test and scale their products, in addition to meeting with mentors and potential investors. The application process is open now.

TurtleTree Scientific Partners With JSBiosciences to Develop Cell Culture Media at Commercial Scale

TurtleTree Scientific, the B2B arm of cellular ag company TurtleTree Labs, announced today a new partnership with JSBiosciences to collaborate on the development of cell culture media. The overarching goal of the partnership is to bring down the cost of production for cell-cultured products in order to eventually achieve commercial scale.

Singapore-based TurtleTree Labs is best known for its technology that produces human milk from mammalian cells. The company launched its TurtleTree Scientific arm earlier this year with the goal of creating food-grade growth factors for cultured protein products.

Finding a growth media that is accessible, affordable, and that doesn’t rely on animals to get remains one of the biggest challenges for cultured protein companies. Some companies are now trying to distance themselves from the use of the controversial fetal bovine serum (FBS), but alternatives are few and far between, not to mention wildly expensive. 

JSBiosciences is a valuable partner in this area because it already has a successful track record of developing mammalian cell culture media at a large scale. The company will provide TurtleTree with food-grade basal media and media formulation services, with the goal of getting “upstream” production costs low enough to allow for commercial-scale production of cell-cultured products, starting in Singapore.

This is the second major partnership for TurtleTree Scientific so far in 2021. Last month, the company announced a collaboration with biotech company Dyadic International. Through that partnership, the two companies are developing recombinant food-grade growth factors for proteins that can be grown in high yields at lower costs in bioreactors.

Cell-Cultured Fish Startup Bluu Biosciences Raises €7 million

Bluu Biosciences, a startup making cell-based fish, has raised a €7 million (~$8.24M USD) round of funding. TechCrunch was first to report the news, writing that Manta Ray Ventures, Norrsken VC, Be8, CPT Capital and Lever VC all participated in the round.

The Berlin, Germany-based Bluu is working on creating cell-based versions of salmon, trout and carp. Though there are more companies tackling the creation of cell-based beef and chicken, there is an emerging wave (pardon the pun) of startups making cultured fish protein. Bluu is focused on salmon, trout and carp. Here in the U.S. BlueNalu is working on cell-based mahi-mahi and bluefin tuna. And in Asia, the Hong-Kong-based Avant Meats is developing fish maw and sea cucumber, while Singapore-based Shiok Meats is making cultured shellfish.

Funding for cell-based protein startups continues to be heavy. A recent report from the Good Food Institute found that cultured meat startups raised $360 million in 2020. Just this week, Eat Just, which makes cell-based chicken that is actually for sale in Singpaore, raised an additional $200 million.

While cell-based fish products aren’t for sale yet, they are getting closer to market. BlueNalu is building out its pilot production facility, which will make 200 – 500 pounds of commercial grade cultured fish. Shiok plans to have it shrimp commercially available by 2022. And Avant recently announced a 90 percent cost reduction in the production of its fish maw.

All of this funding and progress is helping narrow the availability window of cultured meat products with some experts predicting it will hit price parity with traditional animal protein in five years.

Startups: Applications Are Open for Big Idea Ventures’ Alt-Protein Accelerator

Alt-protein food tech accelerator Big Idea Ventures (BIV) announced this week that it is now taking applications for its fourth cohort. According to a press release sent to The Spoon, the five-month-long program will take place in three locations this time: New York, Singapore, and Paris.

For these accelerators, Big Idea Ventures looks for companies developing both plant-based and cultured protein products and ingredients. Food tech companies related to the alt-protein space are also encouraged to apply.

Beside $125,000 in cash investment and $75,000 on in-kind investment, chosen companies also get access to coworking space, including test kitchens, for the duration of the program, as well as mentorship and networking opportunities. Companies will also get to interact with BIV’s limited partners, a group that includes AAK, Bühler Group, Givaudan, Tyson Ventures, and others. 

Chosen companies will ideally have an initial product already validated through sales and ready to scale. On the program’s website, BIV says it is looking specifically for companies developing plant-based products, cellular ag companies, ingredient creators, and those making enabling technologies. 

Because of the pandemic, cohort four will be remote as of this writing. This is a tactic that’s been used by other food tech accelerators over the last year, and a trend that will likely continue for the foreseeable future. For BIV participants, this is actually advantageous, as the organization says companies can leverage resources from all three programs, even if they are only enrolled for one.  

Those interested in applying to BIV’s program can do so here. Applications are taken on a rolling basis, which means the sooner the better in terms of turning one in.

TurtleTree Scientific and Dyadic to Develop Affordable Growth Factors for Cell-Based Proteins at Scale

TurtleTree Scientific, the recently launched B2B unit of TurtleTree Labs that develops growth factors for cellular ag, today announced a “fully funded” collaboration with biotech company Dyadic International. Through this partnership, the two will develop recombinant food-grade growth factors for proteins that can be grown in high yields at lower costs in bioreactors. This could allow TurtleTree, which makes cell-cultured products (including human breastmilk) to scale up and get to market faster, paving the way for cultured meat and dairy companies to do the same.

Dyadic is known for its its C1 gene expression based on the Thermothelomyces heterothallica fungus. Via this platform, Dyadic can produce recombinant proteins at an industrial scale of up to 500,000 liters, with lower capital and operating expenditures than what cultured meat companies would normally find. The company’s tech has been used by some of the world’s most well-known biotech companies, including DuPont and BASF.

In a statement, TurtleTree cofounder and Chief Strategist Max Rye said that manufacturing human growth factors both at scale and at an affordable cost has been a major challenge, and that the partnership with Dyadic will help the company “overcome this hurdle” safely and efficiently.

Growth factors account for the bulk of the cost in cell-based protein production — 55 to 95 percent, by some accounts. Part of the reason for this, TurtleTree explained last month, is that cell culture media components have been developed for non-food areas like research and theraputics, which do not have the same scale requirements and cost constraints as food and agriculture production.

Ronen Tchelet, PhD, Dyadic’s Vice President of Research and Business Development, said in today’s press release that the company will engineer “hyper-productive” C1 cel lines to develop high bioactivity and yields suitable for commercial-scale productions. This will not only accelerate the timeline for TurtleTree’s business, it could also, according to Rye, “make cellular agriculture a reality for all” by enabling food-grade growth factors at an affordable price point to the wider cellular ag industry.